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ABSTRACT 
Objectives: To determine duration of signs and symptoms and 
adverse reactions after treatment with amoxicillin of patients with 
fever and sore throat due to non-exudative pharyngotonsillitis. 
Design: This was a randomized, double-blinded, placebo- 
controlled trial. Outpatients at four medical centers were 
enrolled. Patients over 5 years of age presented with fever and 
sore throat for less than 10 days due to non-exudative pharyn- 
gotonsillitis. Cases with any of the following symptoms or ill- 
ness were excluded: earache, nasal discharge with foul smell, 
rheumatic fever, valvular heart disease, renal disease, and peni- 
cillin hypersensitivity. Amoxicillin or identical placebo at the 
dosage of 50 mg/ kg per day was given three or four times daily 
for 7 days. 
Results: There were 1217 patients enrolled in this study. Some 
were lost to follow-up, which is the reason for the variability in 
number of cases in these analyses. After therapy, duration of 
fever was 2.46 and 2.48 days (P = 0.78) and of sore throat 3.01 
and 3.04 days (P = 0.80) in amoxicillin (n = 431) and placebo 
(n = 436) groups, respectively. Complications were clinically 
documented in 13 (2.5%) and 16 (3.0%) cases in amoxicillin 
(n = 527) and placebo (n = 524) groups (P = 0.56). Two cases 
(0.46% and 0.46%) from each group (n= 433 and 431) were 
positive by antistreptolysin 0 antibody determination. The his- 
tory of carditis and abnormal urinalysis after treatment were 
not obtained. 
Conc/usions: Amoxicillin therapy for non-exudative pharyngo- 
tonsillitis conferred no beneficial or harmful effect. 
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When fever with sore throat is encountered along with 
other symptoms associated with upper respiratory tract 
infection &RI), it may indicate group A streptococcal 
infection or a viral infection.’ It may not be possible to 
clinically discriminate between viral and bacterial etio- 
logies in most cases, owing to similar and non-specific 
symptoms and signs.2,3 Some practitioners favor using 
antimicrobial therapy, even when a viral etiology is sus- 
pected, to provide prophylaxis against the superimposed 
bacterial infection that can develop in the course of a 
viral URI. Others use antibiotics in the hope of shorten- 
ing the duration of fever and sore throat and of easing 
concerns of the doctor about missing a group A strep- 
toccocal infection.* 
With careful and thorough examinations, clinical 
clues suggestive of viral or bacterial URI are evident in 
most cases. For instance, bilateral cervical lymph- 
adenopathy, shallow ulcers in the oral mucosa, small vesi- 
cles on the soft palate, and erythematous nodules on the 
posterior pharyngeal wall indicate non-exudative pharyn- 
gotonsillitis most likely caused by a virus. Bacterial 
pharyngotonsillitis is most likely if there is either follic- 
ular or exudative tonsillitis, where pustules are visible on 
the tonsil surface, or where there is unilateral and tender 
mandibular lymphadenopathy Those patients who do not 
exhibit such clinical clues are usually classified as having 
non-exudative pharyngotonsillitis. By these clinical crite- 
ria, the majority of patients with fever and sore throat 
fall into the category of non-exudative pharyngotonsilli- 
tis and are presumed to have a viral infection. 
However, recent evidence has revealed that anti- 
microbials still frequently are prescribed for this condi- 
tion.“6 In Thailand, antimicrobials were prescribed in 
73% of 52 visits made by five healthy female volunteers 
who presented themselves to general practitioners with 
mock symptoms of fever and sore throat.4 Reasons for 
prescribing amoxicillin for a non-exudative pharyngo- 
tonsillitis sought from 104 other general practitioners 
were similar to explanations from previous studies.‘z8 
Several studies have showed no9-l7 or modest bene- 
fits of antimicrobial therapy for various forms of URI.” 
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However, these studies did not focus on the issue of fever 
and sore throat due to non-exudative pharyngotonsillitis 
nor did they determine the prevalence of group A strep- 
tococcal infection among these patients. Since amoxi- 
cillin is most frequently prescribed for pharyngitis,4~5~18 
the authors’ goal was to determine its efficacy and to 
determine the rate of group A streptococcal infection 
among patients with fever and sore throat due to non- 
exudative pharyngotonsillitis. 
PATIENTS AND METHODS 
The study was a randomized, double-blind, placebo- 
controlled trial. Consecutive patients were recruited, 
prospectively, at four community-based medical centers 
from June 1995 to October 1996. For each study site, ran- 
domized blocks of 32 patients were predetermined, and 
the code was sealed in an envelope. Patients who were 
over 5 years of age who complained of fever and sore 
throat for less than 10 days and who did not have exuda- 
tive infection of throat, ear inflammation, paranasal 
sinuses, and lung or upper airway obstruction were eli- 
gible. All patients were interviewed and those with a his- 
tory of penicillin allergy, valvular heart disease, or renal 
disease, or who had taken an antimicrobial in the previ- 
ous week, were excluded. Pregnant women or breast- 
feeding mothers also were excluded as well as those who 
were unable to comply with the follow-up scheme. The 
details of the study were explained, and the patients them 
selves, or their parents if they were children, agreed to 
enroll in it. The study proposal was reviewed and agreed 
upon by the Ethical Committee of the Faculty of Medi- 
cine, Siriraj Hospital, Mahidol University 
At the patient’s initial visit, blood was collected to 
determine antistreptolysin 0 (ASO) antibody level, and 
urinalysis was performed to detect protein and the pres- 
ence of white or red blood cells. Identical sealed capsules 
contained amoxicillin or a placebo. Syrup for children 
was stored in brown bottles. Amoxicillin-containing cap- 
sules (usual dose: 1 capsule (250 or 500 mg] 3 or 4 times 
daily) or syrup was given for 7 days at a dose of 
50 mg/kg per day in three or four divided doses. The 
placebo was given with the same dosage and duration 
of treatment. Other medications, such as paracetamol, 
acetylsalicylic acid, or chlorpheniramine, also were given 
if physicians deemed it necessary. The patients were 
asked to return to the clinic at day 4 with their 
envelopes, for a pill count. Physical examination was per- 
formed to detect any complications. At day 18, informa- 
tion was gathered about their recent illness, symptoms 
related to complications, adverse reactions, and duration 
of fever and sore throat, in those who recovered with- 
out complications. Blood was collected again for AS0 
antibody determination (the “convalescent” antibody 
level), and urinalysis was repeated. At day 60, any his- 
tory of recent and persistent dyspnea, fatigue, and pedal 
edema for at least 7 consecutive days was documented. 
Auscultation was repeated to detect any new cardiac 
murmurs. A third urinalysis was done, and the results 
were compared to the first and second tests to detect 
any evidence of glomerulonephritis. 
The AS0 was determined by an automated analyzer 
using a turbidimetric immunoreaction, as reported else- 
where.19T2o The quantitation of AS0 antibody was done 
blindly, and the results were expressed in units per milli- 
liter by comparison with a reference serum of known AS0 
value. A positive result was considered to be a fourfold 
increase of ASO-antibody concentration with a conva- 
lescent antibody concentration of over 270 U/mL in a 
Thai population.20 
Non-exudative pharyngotonsillitis was defined by the 
absence of visible pus or pustules on the surface of the 
tonsils or pharynx. There had to be no unilateral tender 
lymph nodes in the submandibular area. There could be 
a cough, but it must be only infrequent. Rheumatic cardi- 
tis was diagnosed clinically if exertional dyspnea per- 
sisted for at least 1 week, or if there was a new audible 
cardiac murmur or pericardial rub. Glomerulonephritis 
was suspected if bilateral pedal edema was present for at 
least 1 week. Alternatively, it was suspected if abnormal 
amounts of protein and red blood cells were detected 
together on the second or third urinalysis. The presence 
of red or white cell casts on the second or third urinal- 
ysis also indicated renal involvement. 
For sample size determination, the prevalence of 
group A streptococcal infection was estimated to be 0.05 
t 0.025 with type one error at 0.05, and thus 292 cases 
were needed. For comparison of complications between 
groups, the probability of suppurative complication in 
the amoxicillin and placebo groups was set at 0.01 and 
0.05, respectively Type one and two errors were at 0.05 
and 0.1, respectively, and compliance to the follow-up 
schedule was about 85%. Therefore, the total number of 
subjects needed per group was 458 cases. The sample 
size needed to detect a half-day difference in the dura- 
tion of fever or sore throat between the groups was cal- 
culated according to the following estimates. The duration 
of fever was estimated to be 3.0 days after treatment for 
amoxicillin and 3.5 days for placebo, with a standard devi- 
ation of 2 days. The type one and two errors were set at 
0.05 and 0.1. Thus 340 cases per group were required. 
All statistical tests were performed with SPSS version 7.5 
(SPSS Inc., New York, NY). Univariate analyses to com- 
pare amoxicillin and placebo recipients included chi- 
square tests for categoric variables, and all continuous 
data, such as durations (d) of fever and sore throat, were 
analyzed with Student’s t-test. All tests of statistical sig- 
nificance were two-sided. A P-value of less than 0.05 indi- 
cated statistical significance. 
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RESULTS 
There were 1217 patients (486 [40%] male; 694 [57%1 
female; 37 not indicated in data) with fever and sore 
throat enrolled in the study: 606 cases in the amoxicillln 
group and 611 cases in the placebo group. The mean 
(t SD) age of the patients was 22.0 + 12.3 years (range, 
6-77 y) in the amoxicillin group and 22.8 + 13.0 years 
(range, 6-71 y) in the placebo group. About 56% of parti- 
cipants in both groups were female. The distribution of 
age and the dates of enrollment in the study were simi- 
lar in each group, although the data were incomplete in 
a few cases. Most patients were 16 to 30 years old and 
were enrolled between October and December. The clii- 
cal indications in each group were similar, and included 
headache, myalgia, and cough (Table 1). 
A similar prevalence of physical findings of con- 
junctiva, soft palate, uvula, posterior pharyngeal wall, and 
tonsils was noted in both groups (Table 2). Congested 
conjunctiva were found in 11.2 to 11.5% of patients. 
Mucosa at the soft palate showing erythema, ulcers, or 
small vesicles was found in approximately 11% of both 
groups. Abnormal tonsils, which were either inflamed, 
enlarged, or both, were found in 41 to 43% of patients. 
At days 4,18, and 60 after enrollment, the number of 
patients returning for follow-up was 459,435, and 369 in 
the amoxicillin group and 460, 443, and 386 in the 
placebo group. There were similar durations of fever and 
sore throat before and after treatment with amoxicillin or 
placebo (Table 3). After treatment, the duration of fever 
was 2.46 and 2.48 days and of sore throat was 3.01 and 
3.04 days, in the amoxiciIlin and placebo groups, respec- 
tively The 95% confidence interval (CI) for the difference 
of duration of fever in the patients treated with amoxi- 
cillin or placebo was -0.2, 0.1, and of sore throat was 
-0.3,0.2, respectively 
Complications developed in 13 (2.5%) (95% CI = 
1.3-4.2) and I6 (3.0%) (95% CI = 1.8-4.9) cases in amox- 
icillin and placebo groups, respectively (P = 0.56) (Table 
4). No data were available on superimposed infection in 
166 cases from both groups because they were lost to fol- 
low-up at days 4 and 18; they could not be contacted by 
mail or telephone, or visited at home. One case in the 
Table 1. Symptoms Associated with Fever and 
Sore Throat, by Drug Group, at Enrollment 
Symptoms 
Amoxici//in* Placebo+ 
n (%I n (%) P-Value 
Fever with chill 
Headache 
Myalgia 
Sneeze 
Stuffed-up nose 
Runny nose 
Cough 
Rash 
117 (19.8) 109 (18.5) 0.5829 
478 (80.9) 474 (80.5) 0.8604 
396 (67.0) 396 (67.2) 0.9337 
234 (35.6) 221 (37.6) 0.4788 
273 (46.2) 274 (46.6) 0.8889 
376 (63.7) 365 (62.1) 0.5569 
353 (59.8) 358 (60.8) 0.7388 
2 (0.3) 0 0.4995 
*Data available in 590 to 591 cases: +data available in 588 to 589 cases. 
Table 2. Physical Findings, by Drug Group, at Enrollment 
AmoxicilIin* Placebof 
Physical Findings n = 597 (100%) n = 589 (700%) P-Value 
Conjunctiva 
Normal 525 (88.8) 521 (88.5) 0.8380 
Congested 66 (11.2) 68 (11.5) 
Soft palate 
Normal 372 (62.9) 370 (62.8) 0.9663 
Erythema 125 (21.2) 129 (21 .Q) 
Ulcer 1 (0.2) 0 
Petechiae 3 (0.5) 2 (0.3) 
Vesicles 69 (11.7) 66 (11.2) 
Erythema & petechiae 1 (0.2) 
Petechiae & vesicles 20 (3.4) 220 (3.7) 
Uvula 
Normal 455 (77) 448 (76.1) 0.7072 
Injected 136 (23.0) 141 (23.9) 
Posterior pharygeal wall 
Normal 189 (32) 188 (31 .Q) 0.9651 
Erythematous plaque 98 (16.6) 101 (17.2) 
Erythematous nodules 301 (51 .O) 298 (50.6) 
Etythematous plaque 3 (0.5) 2 (0.3) 
& nodules 
Tonsil (right) 
Abnormal 258 (43.7) 257 (43.6) 0.9940 
Tonsil (left) 
Abnormal 243 (41 .I) 253 (42.9) 0.5226 
*Data available for analysis in 591 cases; +data available in 589 cases. 
placebo group developed bronchopneumonia and 
needed hospitalization. This patient soon recovered and 
was discharged after 7 days. The most common compli- 
cation was bronchitis, which was found in 10 cases in 
each group. Rheumatic carditis and glomerulonephritis 
were not detected in any patient by history, physical 
examination, or abnormal urinalysis at days 18 and 60. 
Adverse reactions associated with therapy in the 
amoxicihin and placebo groups were found in 1.9% (95% 
CT = 0.9-3.5) and 1.3% (95% CI = 0.5-2.7) respectively 
(P = 0.48). Nausea, vomiting, or epigastric distress devel- 
oped in four patients in the amoxicillin group and in 
three cases in the placebo group, and one case in each 
group developed diarrhea. Two cases in the amoxicillin 
group developed an extensive rash at days 2 and 7, 
although a history of drug reaction had not been elicited 
before enrollment. The study drug was stopped, and the 
rash gradually disappeared. In three additional cases in 
the amoxicillin group, a mild rash developed. In these 
cases, the drug was continued and the rash disappeared. 
Three cases in the placebo group also developed a mild 
rash that cleared up spontaneously 
Patients were divided into five classes by the ratio of 
convalescent to acute AS0 antibody concentration. The 
patients whose AS0 ratio fell below 1, or between 1 and 
1.99,2.0 and 2.99, or 3.0 and 3.99, or at 4 and over, were 
similar for amoxiclllin (n = 433) and placebo (n = 431) 
groups (Table 5). A less than fourfold increase in conva- 
lescent AS0 antibody level was noted in 99% of cases in 
both groups. Four cases in each group had at least a four- 
fold antibody increase, but only two in each group met 
all the criteria for a positive result (Table 6). Hence, the 
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Table 3. Duration of Fever and Sore Throat before and after Treatment, by Drug Group 
Durations of Fever or Sore Throat (d) 
Mean ? SD (Number of Cases) 
95% Cl of Difference 
Amoxicillin Placebo of the Duration 
2.06 2 1.19 (584) NA 0.0670 
2.18 2 1.23 (591) 2.31 2 1.71 (588) NA 
2.46 2 1.27 (431) 2.48 k 1.30 (436) -0.2, 0.1 
3.01 t 1.84 (431) 3.04 ? 1.86 (436) -0.3, 0.2 
Variable 
Before treatment 
Fever 1.97 2 1.08 
Sore throat 
After treatment 
Fever 
Sore throat 
P-Value 
0.0870 
0.7780 
0.7990 
NA = not applicable 
overall prevalence of associated group A streptococcal 
infection was 4 of 864 cases or 0.463% (95% CI = 
0.1473-1.1129). 
DISCUSSION 
This study has limitations owing to some missing data. 
Due to financial constraints, it was not possible to have 
monitors for each study site. However, the amount of miss- 
ing data was small. Some participants with overdue follow- 
up schedules were contacted by mail, telephone, or even 
by a home visit, to determine whether they had any symp- 
toms of carditis, glomerulonephritis, or adverse reactions. 
These methods of communication aided the analysis of 
results by providing some of the missing information at 
each follow-up period. This explains the variable numbers 
of blood or urine samples or information in each group. 
The randomization of patients was satisfactory since base- 
lime data of each group were comparable. 
Study results reveal that for these clinical indications 
amoxiciUin therapy is not effective in shortening the dura- 
tion of fever and sore throat and does not produce more 
adverse reactions than placebo. Most patients reported 
their recovery from the presumably viral infections 
occurred 2 to 4 days after treatment with either amoxi- 
cillin or placebo. Results of this study confirm the con- 
clusions of previous trials9-” that an antimicrobial is 
unnecessary for therapy or prophylaxis in most URI. This 
also holds true for non-exudative pharyngotonsillitis. 
Treatment may increase adverse reactions. Tkvo patients 
who had denied having a penicillin allergy developed a 
typical ampicillin rash during this study. In view of pro- 
phylaxis of possible superimposed bacterial infection, a 
premature administration of an antimicrobial only 
replaces susceptible bacteria or normal flora inside the 
Table 4. Number of Patients with Complications, by Drug Group 
Type of Amoxicillin Placebo 
Complication n = 527* n = 524* P-Value 
Follicular tonsillitis 3 5 0.5617 
Bronchitis 10 10 
Bronchopneumonia 
13 (205%) 
1 
Total 16 (3.0%) 
95% Cl 1.3-4.2 1.8-4.9 
l Number of patients who were followed up at days 4, 18, or 60; 166 cases 
were lost to follow-up. 
body with resistant bacteria soon after antimicrobial 
administration.21-23 
Prevalence of group A streptococcal infection in this 
group of patients was 0.46% (95% CI = 0.147-1.1 13).24 
A new automated imrnunoturbidimetric method was used 
to avoid inherent problems by the conventional Rantz- 
Randall method.25 Throat swab culture for group A strep- 
tococcus was not performed, since its presence can be 
interpreted as pharyngeal infection or carrier. Nonsup- 
purative sequelae did not follow in four cases of “sub- 
clinical” group A streptococcal infection, but the sample 
size is too small to draw any conclusion. The sequelae 
may not occur due to the non-exudative nature of pha- 
ryngeal inflammation, since the liieliiood of developing 
rheumatic fever was believed to be associated with exu- 
dation and a large increase of AS0 titer.26 In a pioneer- 
ing study to prevent rheumatic fever by giving benzathine 
penicillin to patients with fever and sore throat, rheumatic 
fever occurred in 17 cases among 804 untreated patients, 
(2.1 1%).26 In another large group of urban children, less 
than 0.5% of patients with streptococcal pharyngitis 
developed these complications.27 These studies were 
done a decade apart. 
In conclusion, the prevalence of group A strepto- 
coccal infection in non-exudative pharyngotonsillitis is 
low. Amoxicillin can neither shorten the duration of ill- 
ness nor prevent superimposed infection. It can cause 
an adverse reaction in patients who have no history of 
penicillin allergy, although this happens rarely. Changing 
the pattern of current prescribing behavior in the clini- 
cal setting is challenging. A national center for monitor- 
ing cases with newly diagnosed rheumatic fever and 
carditis should be set up to assess the situation of non- 
Table 5. Patients Classified by the Increase of 
Convalescent AS0 Antibody, in Both Groups 
AS0 Ratio* 
< 0.99 
1-l .99 
2-2.99 
3-3.99 
Amoxicillin Placebo 
n = 433+ (100%) n = 431+ (700%) P-Value 
216 (49.9) 199 (46.2) 0.513 
202 (46.6) 214 (49.7) 
11 (2.6) 12 (2.8) 
0 2 co.41 
>4 4 (0.9) 4 (0.9j 
‘Convalesent ASO: initial ASO: *number of oatients who returned for follow-up 
at day 18 or between 18 and 60 days after enrollment and serum samples were 
available for determination of acute and convalescent AS0 antibodies. 
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Table 6. Age, Sex, and AS0 Values of Cases Who 
Exhibited at Least a Fourfold Increase of AS0 Antibody 
Group 
Sex Age 
(M/Q (yl 
AS0 Antibody Increase in 
Antibody 
Day 1 Day 18 (U/m L) 
Amoxicillin 
Case 1 M 7 131 567 X4.33 
Case 2 M 12 204 850 x4.17 
Case 3 M 18 22 158 x7.18* 
Case 4 F 34 26 209 x8.04* 
Placebo 
Case5 F 7 110 1053 x9.57 
Case 6 F 23 27 346 x12.81 
Case 7 M 25 32 143 x4.47* 
Case 8 F 28 12 58 x4.83* 
*Rising of AS0 value greater than fourfold was not significant, owing to the 
convalescent AS0 value less than 270 U/mL. 
suppurative sequelae after the “no antimicrobial” man- 
agement for non-exudative pharyngotonsillitis is fully 
implemented. 
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